Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines
Authors:
Open Access
- 23 January 2025
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2455240
Abstract
The dissemination of tumor cells with ensuing metastasis is responsible for most cancer-related deaths. Cancer vaccines may, by inducing tumor-specific effector T cells, offer a strategy to eliminate metastasizing tumor cells. However, several obstacles remain in the development of effective cancer vaccines, including the identification of adjuvants that enhance the evolvement and efficacy of tumor-specific T cells. Cholera toxin-based adjuvants have shown efficacy in vaccines for infectious diseases, but their role in cancer vaccine therapies remains to be elucidated. Here, we explored the potential of cholera toxin A1 (CTA1)-based adjuvants to boost anti-tumor T cell responses and protect against metastasis. We report that an adjuvant where CTA1 was fused to a dimer from Staphylococcus aureus protein A (DD) enhanced immune responses against the tumor-associated antigens TRP2 and Twist1 in mice, providing protection against B16F1 melanoma and 4T1 breast cancer metastasis, respectively. Both mucosal (intranasal) and systemic (intraperitoneal) vaccine administration provided effective protection against intravenously injected tumor cells, with intranasal administration leading to superior induction of CD4+ T cells at metastatic sites. When comparing antigens admixed with CTA1-DD to those fused with a CTA1-based adjuvant, the fusion construct elicited the strongest immunogenicity. Nevertheless, by administrating a 20-fold higher antigen dose also the admix formulation provided efficient protection against metastasis.Keywords
Funding Information
- Svenska Forskningsrådet Formas
- the Swedish Cancer Society
- The Swedish state via the ALF agreement
- the Assar Gabrielsson Foundation
- The Wilhelm and Martina Lundgren Research Foundation
- Anna-Lisa och Bror Björnssons Stiftelse
This publication has 38 references indexed in Scilit:
- Recent progress in mucosal vaccine development: potential and limitationsNature Reviews Immunology, 2012
- Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosisBlood, 2012
- Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor EffectsCancer Research, 2009
- CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccineVaccine, 2008
- Expression of the Transcription Factors Snail, Slug, and Twist and Their Clinical Significance in Human Breast CancerAnnals of Surgical Oncology, 2005
- Epithelial-Mesenchymal TransitionsCell, 2004
- Dendritic CellsCell, 2001
- Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeuticImmunology Today, 1999
- The Three-dimensional Crystal Structure of Cholera ToxinJournal of Molecular Biology, 1995
- Molecular characterization of a human tyrosinase‐related‐protein‐2 cDNAEuropean Journal of Biochemistry, 1994